Sinovac Biotech Ltd. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 448.27 million compared to USD 1,492.76 million a year ago. Net loss was USD 99.92 million compared to net income of USD 113.87 million a year ago.

Basic loss per share from continuing operations was USD 1.06 compared to basic earnings per share from continuing operations of USD 1.08 a year ago. Diluted loss per share from continuing operations was USD 1.06 compared to diluted earnings per share from continuing operations of USD 1 a year ago.